ObjectiveTo systematically review the efficacy of mobile health (mHealth) apps on weight loss.MethodsWeb of Science, PubMed, CNKI, WanFang Data and CBM databases were electronically searched to collect randomized controlled trials (RCTs) on the efficacy of mHealth APPs on weight loss from inception to October 18, 2019. Two reviewers independently screened literature, extracted data and assessed risk of bias of included studies. Meta-analysis was then performed using RevMan 5.3 software.ResultsA total of 12 RCTs involving 1 074 patients were included. The results of meta-analysis showed that the apps group was superior to the control group in body weight (MD=−1.88, 95%CI −3.23 to −0.53, P=0.006). There was a decreasing trend of body mass index (BMI) in apps group (MD=−0.55, 95%CI −1.09 to 0.00, P=0.05).ConclusionsCurrent evidence shows that mHealth app can increase the efficacy of weight loss. Due to limited quality and quantity of the included studies, more highquality studies are required to verify above conclusions.
ObjectiveTo compare the clinical outcomes of transcatheter aortic valve implantation (TAVI) in oncology and non-oncology patients with severe aortic stenosis (AS).MethodsA computer-based search in PubMed, The Cochrane Library, EMbase, CBM, CNKI and Wanfang databases from their date of inception to December 2021 was performed, together with reference screening, to identify eligible clinical trials. Two investigators screened the articles, extracted data, and evaluated quality independently. RevMan 5.3 and Stata 12.0 softwares were used for meta-analysis.ResultsThe selected 8 cohort studies contained 57 988 patients, including 12 335 cancer patients and 45 653 non-cancer patients. The results of meta-analysis showed that in patients with cancer, the 30-day mortality [OR=0.74, 95%CI (0.65, 0.84), I2=0%, P<0.000 01], stroke [OR=0.87, 95%CI (0.76, 0.99), I2=0%, P=0.04] and acute kidney injury [OR=0.81, 95%CI (0.76, 0.85), I2=49%, P<0.000 01] were lower than those in patients without cancer. The 1-year mortality [OR=1.46, 95%CI (1.15, 1.86), I2=62%, P=0.002] and late mortality [OR=1.51, 95%CI (1.24, 1.85), I2=61%, P<0.000 1] were higher in patients with cancer.ConclusionIt is effective and safe in cancer patients with severe AS undergoing TAVI. However, compared with patients without cancer, it is still high in long-term mortality, and further study of the role of TAVI in cancer patients with AS is necessary.